ELD615
Chronic Lung Diseases (e.g., CF, COPD)
PreclinicalActive
Key Facts
Indication
Chronic Lung Diseases (e.g., CF, COPD)
Phase
Preclinical
Status
Active
Company
About Eldec Pharmaceuticals
Eldec Pharmaceuticals is a private, preclinical-stage biotech founded in 2018 and headquartered in Durham, North Carolina, USA. The company leverages its proprietary 'Lung Peptidome' discovery platform to develop optimized peptide therapeutics targeting chronic lung diseases like cystic fibrosis and COPD. With a seasoned leadership team and non-dilutive grant funding from entities like the NHLBI, Eldec is advancing its lead program, ELD615, which has shown promise in reversing lung damage in animal models. The company represents a novel approach in a high-need therapeutic area with significant market potential.
View full company profile